Anagenics Limited · ASX:AN1
Anagenics — Shareholder Meeting (December 2021)
17 slides from Anagenics's shareholder meeting presentation, Dec 9, 2021
Slide 1: Annual General Meeting of Shareholders CEO Presentation
9 December 2021 ASX: CDY ANNUAL GENERAL MEETING OF SHAREHOLDERS CEO PRESENTATION 1
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation has been prepared by Cellmid Limited ACN 111 304 119 (CDY or Company) for information purposes only. The presentation may contain forward- looking statements that are not guarantees of future performance and are subject to risks and uncertainties. Such fo
Slide 3: Agenda
AGENDA ● Cellmid ● FY2021 Highlights ● Financial Information ● Pandemic Response ● BLC Acquisition ● FY2022 Outlook ● Introducing Anagenics ● ESG Statement 3
Slide 4: A health and beauty-tech business with global distribution
A health and beauty-tech business with global distribution and sales of proprietary and licensed brands of differentiated, clinically validated anti-aging and longevity solutions Premium brands, a global distribution footprint and strong sales capabilities into the professional beauty network, DTC a
Slide 5: FY2021 Highlights – Delivering Against Head Winds
FY2021 HIGHLIGHTS – DELIVERING AGAINST HEAD WINDS FY2021 OPERATIONAL HIGHLIGHTS Launched new Launched Signed products: Australian Signed two Pump Hair Jo-Ju EX and US Chinese Care – white Let there be e-commerce distribution label hair platforms agreements agreement Acquired BLC FY2021 FINANCIAL HIG
Slide 6: CDY Profit and Loss Statement FY2021
CDY PROFIT AND LOSS STATEMENT FY2021 Improved operational performance under difficult pandemic conditions with revenue down 21% while loss down 41% (EBITDA loss down 50%) Key areas of savings were research and development expenses and legal fees One off impairment of assets contributed $637K to the
Slide 7: BLC Profit and Loss Statement FY2021
BLC PROFIT AND LOSS STATEMENT FY2021** New brands and distribution points contributed to the revenue growth EBITDA on target at $508k EBITDA normalised for non-recurring items of $1.7 million intercompany loan write off and $310K government support 7
Slide 8: Appendix 4C - Q1 FY2022
APPENDIX 4C - Q1 FY2022 Stabilised costs including employment and operational expenses but invested in manufacturing to secure raw materials Funding to deliver on growth objectives $83K government assistance 8
Slide 9: Building Scale: Pro Forma Financial Position
BUILDING SCALE: PRO FORMA FINANCIAL POSITION* 9
Slide 10: Building Scale: Pro Forma Financial Position
BUILDING SCALE: PRO FORMA FINANCIAL POSITION* 10
Slide 11: Responding to the Impact of the Pandemic
RESPONDING TO THE IMPACT OF THE PANDEMIC SALES SUPPLY CHAIN HUMAN RESOURCES ACQUISITONS • Key US partner, Neiman Marcus shut • Disrupted supply chain with delays in • Large headcount in markets where our sales • Identifying acquisition targets have down for most of the financial year, transport, mat
Slide 12: BLC Transaction Details
BLC TRANSACTION DETAILS Deal Information Strategic Rationale ● Cellmid acquired 100% of BLC Cosmetics (BLC) from HGL ● Scale in market with doubling of Cellmid’s FY2021 revenue and Limited (ASX:HNG) (HGL) other income of $7.3M ● Cellmid paid $3M in the first tranche; $1M in cash and $2M ● The combin
Slide 13: FY2022 Outlook
FY2022 OUTLOOK COVID-19: Immediate growth Continue to invest in Store and salon sales are likely to from BLC acquisition China: Building the Jo-Ju and continue to be affected in the and synergies: evolis brands with CDY’s first half of FY2022 in Australia, With a 1 October 2021 effective settlement
Slide 14: Introducing Anagenics (ASX: AN1)
INTRODUCING ANAGENICS (ASX: AN1)* ΑΝΑΓΕΝΝΗΣΗ ANAGENNISI Anagennisi, the inspiration behind our new name Anagenics, is the Greek word for regeneration. The word is meaningful to our next stage of corporate development in three fundamental ways: • With the sale of Lyramid we have completed the transit
Slide 15: Driven by Environmental, Social & Governance Principles
DRIVEN BY ENVIRONMENTAL, SOCIAL & GOVERNANCE PRINCIPLES • We encourage diversity and respect of all sexes, races, religions and cultures amongst our employees, suppliers, customers and other stakeholders • We are committed to providing high quality, effective and ethical products to our customers •
Slide 16: Evolis on A Current Affair
Evolis on A CURRENT AFFAIR ● https://cellmid.com.au/investors/cellmid-in-the-media/ 16
Slide 17: Thank You
THANK YOU Maria Halasz | CEO info@cellmid.com.au +61 9221 6830 17